Clinical Trials Logo

Dementia With Lewy Bodies (DLB) clinical trials

View clinical trials related to Dementia With Lewy Bodies (DLB).

Filter by:
  • None
  • Page 1

NCT ID: NCT04055532 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Biomarkers in Neurodegenerative Diseases

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

NCT ID: NCT04001517 Completed - Clinical trials for Dementia With Lewy Bodies (DLB)

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

AscenD-LB
Start date: September 30, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.

NCT ID: NCT03030586 Recruiting - Clinical trials for Frontotemporal Lobar Degeneration

ADDIA Proof-of-Performance Clinical Study

ADDIA
Start date: September 1, 2016
Phase:
Study type: Observational

The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD). ADDIA clinical study is a multi-centre, non-interventional, prospective, proof-of-performance study with only one visit. About 800 well-characterized subjects will be recruited into 3 groups in 2:1:1 ratio, namely patients with Alzheimer's disease (AD), patients with non-AD neurodegenerative disease (NAD) and 200 control subjects (healthy as compared to their age). - 400 patients with Alzheimer's disease (AD): 200 patients with mild AD, 200 patients with moderate-to-severe AD, - 200 patients with non-Alzheimer's neurodegenerative diseases (NAD), - 200 controls (healthy as compared to their age).

NCT ID: NCT01278407 Completed - Clinical trials for Dementia With Lewy Bodies (DLB)

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Start date: February 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the efficacy of E2020 in patients with dementia with Lewy bodies (DLB).

NCT ID: NCT00776347 Completed - Clinical trials for Dementia With Lewy Bodies (DLB)

Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Start date: October 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.

NCT ID: NCT00598650 Completed - Clinical trials for Dementia With Lewy Bodies (DLB)

A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).

NCT ID: NCT00543855 Completed - Clinical trials for Dementia With Lewy Bodies (DLB)

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of E2020 in patients with Dementia with Lewy Bodies (DLB).